A Clinical Appraisal of Pentapyrrolidinium (M&B 2050) in Hypertensive Patients

A Clinical Appraisal of Pentapyrrolidinium (M&B 2050) in Hypertensive Patients

Contributor(s):
Lilienfield, Lawrence S.
Partenope, Edward A.
Circulation
Freis, Edward D.
Rose, John C.
Publication:
American Heart Association, April 1954
Language(s):
English
Format:
Text
Subject(s):
Hypertension
Antihypertensive Agents
Hexamethonium
Pentolinium Tartrate
Genre(s):
Archival Materials
Articles
Abstract:
Here, Freis's team studied the effectiveness of pentapyrrolidinium (a ganglionic-blocking agent, also called pentolinium) as an antihypertensive treatment. They concluded that the drug had several advantages in the treatment of severe hypertension over another ganglionic-blocking agent, hexamethonium. The drug's attributes, longer duration of action, greater potency, and a more uniform response to oral administration, more than compensated for its side effects and the frequent need to adjust dosage.
Copyright:
The National Library of Medicine believes this item to be in the public domain. (More information)
Extent:
7 pages
NLM Unique ID:
101584929X43 (See in Profiles in Science)
Profiles in Science ID:
XFBBDB
Permanent Link:
http://resource.nlm.nih.gov/101584929X43
Archival Collection:
The Edward D. Freis Papers (Profiles in Science)